Dr Milan Radovich speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the association between disease recurrence in early-stage triple-negative breast cancer and circulating DNA (ctDNA) and CTCs (circulating tumour cells) after neoadjuvant chemotherapy.
He gives an overview of the study design which used genomic sequencing to sequence residual disease tumours from patients participating in the BRE12-158 study.
Dr Radovich reports the main findings from this study and noted that patients who were ctDNA-positive had an inferior, distant disease-free survival (DDFS) with an estimated DDFS of 56 percent versus 81 percent in patients who were ctDNA-negative.
He believes that future trials should focus on evaluating the use of ctDNA to guide therapy for high-risk patients.
Watch the press conference here.
Read more about the study here.